Trending...
- P-Wave Classics Opens Pre-Orders for Volume II of Robert Bage's Hermsprong
- Mayor Brandon Johnson Announces Appointment of Kenneth Gunn as Commissioner of the Chicago Commission on Human Relations
- AI Is Making It Easier for API-First Platforms to Connect, Partner, Reach Customers, and Grow Revenue Faster
Vulnerable elderly residents face serious risks and premature death from antipsychotics.
LOS ANGELES - illiNews -- By CCHR International
The Citizens Commission on Human Rights International (CCHR), a 57-year mental health industry watchdog, warns that vulnerable elderly residents in some U.S. nursing homes continue to face serious risks of premature death from antipsychotics. Some facilities and their prescribers evade meaningful accountability, and penalties remain too weak to deter the abuse.
The U.S. Department of Health and Human Services Office of Inspector General (OIG) recently issued two reports examining psychotropic drugging in nursing homes. In a review of 40 Centers for Medicare and Medicaid Services (CMS) inspections, the OIG found that some facilities routinely administered antipsychotics—drugs not Food and Drug Administration (FDA)-approved for dementia and linked to increased mortality—to control resident behavior, while frequently failing to implement required safeguards.[1]
"The inappropriate use of antipsychotic drugs in nursing homes has been a longstanding concern for Congress and others," the OIG stated. The reports also addressed how some nursing homes misdiagnose residents with "schizophrenia" to bypass accountability and artificially improve public quality ratings. The OIG recommended that CMS strengthen oversight, closely monitor schizophrenia diagnosis rates, target high-risk facilities, and ensure residents and families receive clear information about antipsychotic use.
CCHR's international president, Jan Eastgate, responded: "For decades, this abuse has been reported, with promises of increased oversight. These latest government reports reinforce that our elderly are being misdiagnosed and plied with debilitating antipsychotics." Current penalties—capped at $1,000–$5,000 for false certifications—are inadequate, she said.
More on illi News
In 2011, OIG Inspector General Daniel Levinson declared: "Government, taxpayers, nursing home residents, as well as their families and caregivers, should be outraged—and seek solutions."[2] In 2023, HHS had identified serious problems with inappropriate antipsychotic use and inaccurate schizophrenia diagnoses, but the agency did not impose substantial financial penalties at the time.[2]
Antipsychotics carry well-documented dangers for the elderly. In 2005, the Food and Drug Administration (FDA) issued a black-box warning for their use in dementia patients due to elevated death risks.[3] In 2007, FDA senior drug safety official Dr. David Graham warned that at least 15,000 nursing home residents die annually from these drugs.[4] A 2024 American Association of Retired Persons report found that in people with dementia aged 50 and older, antipsychotics more than doubled the risk of pneumonia—the leading cause of death in this population—while also increasing risks of stroke, acute kidney injury, blood clots, bone fractures, heart attack, and heart failure.[5]
The problem dates back decades:
1987: Congress passed the Omnibus Reconciliation Act, including the Nursing Home Reform Act, intended to curb chemical restraints; the practice shifted to medication-based "chemical restraints."[6]
2007: Sen. Chuck Grassley called for an OIG review of antipsychotic use and marketing in nursing homes.[7]
2012–2015: CMS's National Partnership to Improve Dementia Care reduced prescribing somewhat, but schizophrenia diagnoses rose sharply, undermining progress.[8]
2019–2020: Roughly 20% of skilled nursing facility residents—about 298,650 people weekly—received antipsychotics. A House Ways and Means report described the crisis as "one of patient harm, inadequate oversight, and insufficient staffing."[9]
More on illi News
Eastgate concluded, "This continued drugging despite repeated investigations needs to change. Accountability is vital because our seniors deserve compassion and safety, not sedation and premature death."
CCHR urges Congress, CMS, and state authorities to enact immediate, enforceable protections—including strong penalties on any prescribers and facilities engaged in such practices—and to prioritize non-drug alternatives for behavioral care in nursing homes.
CCHR is a nonprofit mental health watchdog, established by the Church of Scientology and Professor of Psychiatry, Thomas Szasz, M.D., dedicated to eradicating abuses committed under the guise of mental health care. Since 1969, CCHR has helped secure hundreds of laws protecting individuals from coercive psychiatric practices.
Sources:
[1] Nursing Homes' Inappropriate Use of Antipsychotic Drugs Poses a Risk to Residents, OIG, 16 Mar. 2026, oig.hhs.gov/reports/all/2026/nursing-homes-inappropriate-use-of-antipsychotic-drugs-poses-a-risk-to-residents/
[2] "Overmedication of Nursing Home Patients Troubling," OIG, 1 June 2011
[3] "Nursing Homes Under Investigation for Abuse of Antipsychotics," Newsmax.com, 18 Jan. 2023
[4] Jeanne Lenzer, "FDA warns about using antipsychotic drugs for dementia," BMJ, 23 Apr. 2005,
[5] Testimony by Dr. David Graham, House Hearing, 110th Congress – The Adequacy of FDA to Assure the Safety of the Nation's Drug Supply General, 13 Feb. 2007, p. 66
[6] "Antipsychotics Pose New Risks for People With Dementia," AARP, 24 Apr. 2024, Updated 27 Jan. 2026
[7] P S Masand, "Side effects of antipsychotics in the elderly "J Clin Psychiatry, 2000
[8] "Under-Enforced and Over-Prescribed: The Antipsychotic Drug Epidemic Ravaging America's Nursing Homes." Report of the Committee on Ways and Means Majority U.S. House of Representatives, July 2020, p. 9
[9] "Long-Term Trends of Psychotropic Drug Use in Nursing Homes," Health and Human Services Office of the Inspector General, 11 Nov. 2022
The Citizens Commission on Human Rights International (CCHR), a 57-year mental health industry watchdog, warns that vulnerable elderly residents in some U.S. nursing homes continue to face serious risks of premature death from antipsychotics. Some facilities and their prescribers evade meaningful accountability, and penalties remain too weak to deter the abuse.
The U.S. Department of Health and Human Services Office of Inspector General (OIG) recently issued two reports examining psychotropic drugging in nursing homes. In a review of 40 Centers for Medicare and Medicaid Services (CMS) inspections, the OIG found that some facilities routinely administered antipsychotics—drugs not Food and Drug Administration (FDA)-approved for dementia and linked to increased mortality—to control resident behavior, while frequently failing to implement required safeguards.[1]
"The inappropriate use of antipsychotic drugs in nursing homes has been a longstanding concern for Congress and others," the OIG stated. The reports also addressed how some nursing homes misdiagnose residents with "schizophrenia" to bypass accountability and artificially improve public quality ratings. The OIG recommended that CMS strengthen oversight, closely monitor schizophrenia diagnosis rates, target high-risk facilities, and ensure residents and families receive clear information about antipsychotic use.
CCHR's international president, Jan Eastgate, responded: "For decades, this abuse has been reported, with promises of increased oversight. These latest government reports reinforce that our elderly are being misdiagnosed and plied with debilitating antipsychotics." Current penalties—capped at $1,000–$5,000 for false certifications—are inadequate, she said.
More on illi News
- Meredith Martin Addy Earns Chambers USA Band 1 for 21st Straight Year; AddyHart LLC also Ranked
- Mayor Brandon Johnson Advances Chicago's Labor Standards with Minimum Wage Increase and Strengthened Worker's Rights Ordinances
- Mayor Brandon Johnson, Chicago Department of Public Health Launch Summer Safety Plan to Reduce Violence, Prevent Overdoses, and Connect Residents to Care
- Kushh Combines Portable Comfort, Convenient Storage, and Everyday Versatility
- Mulch Bed Lighting Introduces a Seamless New Approach to Landscape Illumination
In 2011, OIG Inspector General Daniel Levinson declared: "Government, taxpayers, nursing home residents, as well as their families and caregivers, should be outraged—and seek solutions."[2] In 2023, HHS had identified serious problems with inappropriate antipsychotic use and inaccurate schizophrenia diagnoses, but the agency did not impose substantial financial penalties at the time.[2]
Antipsychotics carry well-documented dangers for the elderly. In 2005, the Food and Drug Administration (FDA) issued a black-box warning for their use in dementia patients due to elevated death risks.[3] In 2007, FDA senior drug safety official Dr. David Graham warned that at least 15,000 nursing home residents die annually from these drugs.[4] A 2024 American Association of Retired Persons report found that in people with dementia aged 50 and older, antipsychotics more than doubled the risk of pneumonia—the leading cause of death in this population—while also increasing risks of stroke, acute kidney injury, blood clots, bone fractures, heart attack, and heart failure.[5]
The problem dates back decades:
1987: Congress passed the Omnibus Reconciliation Act, including the Nursing Home Reform Act, intended to curb chemical restraints; the practice shifted to medication-based "chemical restraints."[6]
2007: Sen. Chuck Grassley called for an OIG review of antipsychotic use and marketing in nursing homes.[7]
2012–2015: CMS's National Partnership to Improve Dementia Care reduced prescribing somewhat, but schizophrenia diagnoses rose sharply, undermining progress.[8]
2019–2020: Roughly 20% of skilled nursing facility residents—about 298,650 people weekly—received antipsychotics. A House Ways and Means report described the crisis as "one of patient harm, inadequate oversight, and insufficient staffing."[9]
More on illi News
- Smile Straw Introduces an Innovative Mouthpiece Designed to Encourage a Natural Smile While Drinking
- CarryKeeper Introduces an Innovative Solution for Securing Holstered Gear
- Smile Straw Introduces a Fun and Engaging Twist on Everyday Beverage Accessories
- Label Smart Introduces an Innovative Approach to Organization and Identification
- Guitwainjo Introduces a Unique New Approach to Musical Creativity
Eastgate concluded, "This continued drugging despite repeated investigations needs to change. Accountability is vital because our seniors deserve compassion and safety, not sedation and premature death."
CCHR urges Congress, CMS, and state authorities to enact immediate, enforceable protections—including strong penalties on any prescribers and facilities engaged in such practices—and to prioritize non-drug alternatives for behavioral care in nursing homes.
CCHR is a nonprofit mental health watchdog, established by the Church of Scientology and Professor of Psychiatry, Thomas Szasz, M.D., dedicated to eradicating abuses committed under the guise of mental health care. Since 1969, CCHR has helped secure hundreds of laws protecting individuals from coercive psychiatric practices.
Sources:
[1] Nursing Homes' Inappropriate Use of Antipsychotic Drugs Poses a Risk to Residents, OIG, 16 Mar. 2026, oig.hhs.gov/reports/all/2026/nursing-homes-inappropriate-use-of-antipsychotic-drugs-poses-a-risk-to-residents/
[2] "Overmedication of Nursing Home Patients Troubling," OIG, 1 June 2011
[3] "Nursing Homes Under Investigation for Abuse of Antipsychotics," Newsmax.com, 18 Jan. 2023
[4] Jeanne Lenzer, "FDA warns about using antipsychotic drugs for dementia," BMJ, 23 Apr. 2005,
[5] Testimony by Dr. David Graham, House Hearing, 110th Congress – The Adequacy of FDA to Assure the Safety of the Nation's Drug Supply General, 13 Feb. 2007, p. 66
[6] "Antipsychotics Pose New Risks for People With Dementia," AARP, 24 Apr. 2024, Updated 27 Jan. 2026
[7] P S Masand, "Side effects of antipsychotics in the elderly "J Clin Psychiatry, 2000
[8] "Under-Enforced and Over-Prescribed: The Antipsychotic Drug Epidemic Ravaging America's Nursing Homes." Report of the Committee on Ways and Means Majority U.S. House of Representatives, July 2020, p. 9
[9] "Long-Term Trends of Psychotropic Drug Use in Nursing Homes," Health and Human Services Office of the Inspector General, 11 Nov. 2022
Source: Citizens Commission on Human Rights International
Filed Under: Health, Government
0 Comments
Latest on illi News
- Abbott Painting Co. Celebrates Pride, Creativity, and Community Through "Color Me Proud" Contest
- Agape Leadership Academy Opens Nationwide Enrollment — State ESA Scholarships Cover Full Tuition for Families in 7 States
- Las Vegas Headliner Don Barnhart Brings National Touring Comedy Show to Comedy Cabana
- Nevada Boxing Hall of Fame Announces 14th Annual Induction Gala Weekend Honoring Classes of 2025 and 2026
- Brosix Celebrates 20 Years of Private Team Messaging for Small and Mid-Sized Businesses
- Top 15 Mosquito-Infested Cities in Louisiana and East Texas Ranked for 2026 Mosquito Season
- From Broken to Soaring Week 40
- Finnish Political Satire Film Generates 10,000+ Cross-Platform Interactions Following Gandalf Parody Video Across TikTok, YouTube and Telegram
- Naperville: Structure Fire in the 2100 Block of Citygate Lane
- Yetter Consulting Services, Inc. Named to Inc.'s 2026 Best Workplaces List
- New Book Reveals U.S. Government's First Official Recognition Of UAP-related Service Injury
- Litera Foundation 365 Brings AI Powered Client Intelligence Directly into Microsoft 365
- AI Is Making It Easier for API-First Platforms to Connect, Partner, Reach Customers, and Grow Revenue Faster
- 2026 Editorial Freelancers Association Conference Focuses on Building Sustainable Careers
- Mayor Brandon Johnson and YMCA President & CEO Adam M. Alonso Announce Free Summer YMCA Memberships for Chicago Teens
- netElastic Powers LigaT's High-Performance Broadband Expansion and IPv6 Modernization in Portugal
- Raiku launches rkuSOL with Sanctum, Kamino, Loopscale and Exponent
- Greenland Mines Ltd (N A S D A Q: GRML) Advances Strategic Growth Initiatives as Critical Minerals Demand Accelerates
- Entering the $69 Billion Animal Health Market, Delivering Record Growth, AI-Driven Healthcare Innovation, and Targeting $200 Million Revenue by 2029
- $97.9 Million Q1 Revenue Growth Reinforces Transformation Into a Global AI & Digital Services Powerhouse: IQSTEL, Inc. (N A S D A Q: IQST)
